Thursday, November 12, 2026

Nikkei 225 Jumps By 5% In The Last 5 Sessions

ViaNews Editorial Team

November 7, 2023

Nikkei 225 Jumps By 5% In The Last 5 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 5.69% for the last 5 sessions. At 05:08 EST on Tuesday, 7 November, Nikkei 225 (N225) is $32,444.95.

Concerning Nikkei 225's yearly highs and lows, it's 26.43% up from its 52-week low and 3.93% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was 1.96%, 0.29%, and 0.97%, respectively.

Nikkei 225's highest amplitude of average volatility was 1.96% (last week), 1.24% (last month), and 0.97% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be oversold (<=20).

News about

  • According to MarketWatch on Monday, 6 November, "The company has applied to list on Nasdaq under the ticker "CRGX." The Renaissance IPO ETF has gained 29% in the year to date, while the S&P 500 has gained 13.5%."
  • According to MarketWatch on Monday, 6 November, "In comparison, the Global X Autonomous & Electric Vehicles ETF DRIV has gained 12.3% this year and the S&P 500 index SPX has advanced 13.5%."
  • According to Zacks on Monday, 6 November, "The S&P 500 advanced 5.9%, the Dow Jones added 5.1%, the Nasdaq surged 6.6% and the Russell 2000 jumped about 7% last week on hopes that the Fed is done with its rate-hiking campaign due to weak jobs data. "
  • According to MarketWatch on Monday, 6 November, "The stock has tumbled 27.7% over the past three months through Friday, while the S&P 500 has slipped 2.7%."
  • According to MarketWatch on Monday, 6 November, "Organigram's stock has fallen 64% in the year to date, while the AXS Cannabis ETF has fallen 36% and the S&P 500 has gained 13.5%."

More news about Nikkei 225 (N225).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
Nikkei 225 Jumps By 5% In The Last 5 Sessions | Via News